Stem cell therapy carries a wide range of side effects, from mild injection-site pain to serious complications like organ damage, infection, and secondary cancers. The specific risks depend heavily on the type of procedure: a full stem cell transplant for blood cancers is very different from a regenerative stem cell injection for a joint injury. Both carry real risks, and some side effects can appear months or even decades after treatment.
Early Side Effects in the First Weeks
The most immediate side effects tend to be straightforward. Pain, swelling, or bruising at the injection or catheter site is common. Many patients also experience fever, fatigue, nausea, and headaches in the days following treatment. These symptoms are typically short-lived and manageable.
For patients receiving a full hematopoietic stem cell transplant (the kind used to treat leukemia and other blood cancers), the early weeks bring a more serious challenge: a steep drop in blood cell counts. White blood cells, red blood cells, and platelets all fall dramatically. White blood cell counts usually hit their lowest point 3 to 10 days after the transplant. When the absolute neutrophil count drops below 500, a condition called neutropenia, the body is largely defenseless against infection. Platelet counts can fall below 50,000 (from a normal range of 150,000 to 400,000), raising the risk of uncontrolled bleeding. These counts typically recover to safe levels within two to six weeks, but the window in between is the most dangerous period of the entire process.
Infection Risk After Transplant
Infections are one of the most common and potentially life-threatening complications of stem cell transplants. The risk follows a predictable timeline, broken into three phases.
In the first month, before the new stem cells establish themselves, damaged barriers in the skin and gut lining plus the presence of intravenous catheters create easy entry points for bacteria and fungi. Staph infections, Candida (yeast), and Aspergillus (a common mold) are the primary concerns. Herpes simplex virus can also reactivate during this window.
From roughly one to three months after transplant, the immune system is rebuilding but still weak. Cytomegalovirus (CMV) becomes a critical threat during this phase, potentially causing pneumonia, hepatitis, or inflammation of the colon. A fungal pathogen called Pneumocystis is also a significant risk.
Beyond three months, patients who develop chronic graft-versus-host disease (more on that below) remain vulnerable to respiratory viruses, shingles (varicella-zoster reactivation), and bacterial infections from encapsulated organisms like Streptococcus pneumoniae and Haemophilus influenzae. This late-phase vulnerability can persist for a year or longer.
Graft-Versus-Host Disease
Graft-versus-host disease, or GVHD, is unique to allogeneic transplants, where stem cells come from a donor rather than the patient’s own body. It happens when the donor’s immune cells recognize the recipient’s tissues as foreign and attack them. About 41% of allogeneic transplant patients develop acute GVHD severe enough to require treatment. Of those, roughly 35% experience it in the classic form within the first 100 days, and another 6% develop a late-onset version afterward.
Acute GVHD most commonly targets the skin (causing rashes), the liver, and the gastrointestinal tract (causing diarrhea, nausea, and abdominal pain). Chronic GVHD can appear anywhere from about 100 to 600 days after transplant and may affect the skin, eyes, mouth, lungs, joints, and other organs. It can resemble autoimmune conditions, with dry eyes, tight skin, and difficulty breathing. Chronic GVHD is one of the leading causes of long-term health problems after transplant.
Immune Rejection of Donor Cells
Even when GVHD doesn’t develop, the recipient’s immune system may reject the transplanted cells entirely. This is driven primarily by T cells, a type of white blood cell that identifies and destroys foreign material. Both CD4+ and CD8+ T cells infiltrate the graft site, and macrophages (immune cells that engulf debris) pile on. If rejection is severe enough, the transplant fails and blood counts never recover, which can be fatal without a second transplant or other intervention.
Rejection is less of a concern when patients receive their own stem cells back (autologous transplant), but it’s a meaningful risk with donor cells, particularly when the donor is not a close genetic match.
Long-Term and Late-Onset Complications
Some side effects don’t appear until months, years, or even decades later. The conditioning treatments used before transplant, typically high-dose chemotherapy and sometimes radiation, take a toll on organs throughout the body. The heart, lungs, kidneys, liver, bones, joints, and nervous system can all sustain lasting damage.
Other long-term risks include:
- Secondary cancers: New solid tumors in various organs, leukemia, or myelodysplastic syndromes (a group of bone marrow disorders) can develop years after an autologous transplant.
- Infertility: The conditioning regimen frequently damages reproductive cells permanently.
- Hormonal changes: The thyroid and pituitary glands are particularly susceptible, which can affect metabolism, energy, and growth.
- Cataracts: Clouding of the eye’s lens, especially in patients who received total body irradiation.
- Abnormal lymph tissue growth: Particularly EBV-related lymphoproliferative disease, where certain white blood cells multiply uncontrollably.
These risks are the reason transplant survivors require regular follow-up for years. Screening for secondary cancers, thyroid function, heart health, and bone density becomes a routine part of life after transplant.
Cancer Risk From the Cells Themselves
Beyond secondary cancers caused by chemotherapy and radiation, there’s an inherent biological risk tied to stem cells. Research from Harvard Medical School found that about 5% of lab-grown pluripotent stem cell lines had acquired mutations in p53, a gene that normally suppresses tumor growth. When p53 is disabled, cells are more likely to grow uncontrollably. The organs most relevant to regenerative medicine, including the pancreas, brain, blood, bone, skin, liver, and lungs, are also the tissues most vulnerable to transformation when carrying a p53 mutation.
This concern is especially relevant for experimental regenerative therapies that use lab-cultured cells. The process of growing stem cells in a lab introduces a form of natural selection where mutated cells can outcompete healthy ones, a mechanism that mirrors how cancer develops in the body.
Risks From Unregulated Clinics
A separate category of risk comes from stem cell treatments offered outside the regulated medical system. Hundreds of clinics market stem cell injections for arthritis, back pain, anti-aging, and other conditions without FDA approval. The FDA has issued public safety alerts after patients experienced serious adverse events from unapproved products marketed as containing stem cells or exosomes. These products bypass the safety testing required of legitimate therapies, and patients have no guarantee of what they’re actually being injected with.
The dangers go beyond the injection itself. Patients who pursue unproven treatments may delay therapies that have actual evidence behind them, allowing their underlying condition to worsen. The FDA has been explicit that clinics offering these products outside of its review process are “taking advantage of patients” and putting them at risk of direct harm.